Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/lenacapavir versus stable baseline regimen in virologically suppressed adults with HIV-1 on complex treatment regimens
2022-500929-33-01Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of bictegravir and lenacapavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Planned start May 2023; status: authorised.
02
Drugs
bictegravirlenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2022-500929-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500929-33-01.